Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas

Conclusions: Despite a 57% decline in ambulatory care utilization in the south-central US during March and April of 2020, health services utilization related to buprenorphine in Texas remained robust. Protecting access to buprenorphine as the COVID-19 pandemic continues to unfold will require intensive efforts from clinicians and policy makers alike. While the presented results are promising, researchers must continue monitoring and exploring the clinical and humanistic impact of COVID-19 on the treatment of substance use disorders.
Source: Journal of Addiction Medicine - Category: Addiction Tags: Brief Reports Source Type: research
More News: Addiction | COVID-19 | Pandemics | SARS